{"title":"博氏酵母菌治疗难治性复发性艰难梭菌感染的文献综述","authors":"Rachel Warila, R. Hoover","doi":"10.21620/IJFAAS.2017120-26","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the efficacy of S. boulardii for the treatment of recurrent C. difficile infections. Methods: Eligible articles included S. boulardii in patients with recurrent C. difficile infection. The primary endpoint examined was clinical resolution of infection with no further recurrences during follow-up. Results: Six studies met inclusion criteria. A case report showed resolution of recurrences in one patient, and an experimental trial showed a trend towards decreased recurrences in patients receiving S. boulardii (85% no further recurrences). Two randomized controlled trials found a significant decrease in recurrences for S. boulardii versus placebo (34.6% vs 64.7%, P=0.04; 16.7% vs 50%, P=0.05). One meta-analysis determined significant efficacy for S. boulardii in reducing relapses (RR 0.59, 95% CI 0.35-0.98), while another concluded there was insufficient evidence to recommend probiotics for C. difficile infection. Conclusions: S. boulardii may be considered for patients with recurrent C. difficile infection, refractory to antibiotic regimens alone.","PeriodicalId":13975,"journal":{"name":"International Journal of Food and Allied Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Literature Review of Saccharomyces boulardii in the Treatment of Refractory Recurrent Clostridium difficile Infection\",\"authors\":\"Rachel Warila, R. Hoover\",\"doi\":\"10.21620/IJFAAS.2017120-26\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To evaluate the efficacy of S. boulardii for the treatment of recurrent C. difficile infections. Methods: Eligible articles included S. boulardii in patients with recurrent C. difficile infection. The primary endpoint examined was clinical resolution of infection with no further recurrences during follow-up. Results: Six studies met inclusion criteria. A case report showed resolution of recurrences in one patient, and an experimental trial showed a trend towards decreased recurrences in patients receiving S. boulardii (85% no further recurrences). Two randomized controlled trials found a significant decrease in recurrences for S. boulardii versus placebo (34.6% vs 64.7%, P=0.04; 16.7% vs 50%, P=0.05). One meta-analysis determined significant efficacy for S. boulardii in reducing relapses (RR 0.59, 95% CI 0.35-0.98), while another concluded there was insufficient evidence to recommend probiotics for C. difficile infection. Conclusions: S. boulardii may be considered for patients with recurrent C. difficile infection, refractory to antibiotic regimens alone.\",\"PeriodicalId\":13975,\"journal\":{\"name\":\"International Journal of Food and Allied Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Food and Allied Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21620/IJFAAS.2017120-26\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Food and Allied Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21620/IJFAAS.2017120-26","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
目的:评价博氏梭菌治疗复发性难辨梭菌感染的疗效。方法:符合条件的文献包括复发性艰难梭菌感染患者的博氏梭菌。检查的主要终点是感染的临床消退,随访期间没有进一步复发。结果:6项研究符合纳入标准。一份病例报告显示,一名患者的复发得到缓解,一项实验性试验显示,接受博氏弓形虫治疗的患者的复发率有下降的趋势(85%的患者不再复发)。两项随机对照试验发现,与安慰剂相比,博氏弓形虫的复发率显著降低(34.6% vs 64.7%, P=0.04;16.7% vs 50%, P=0.05)。一项荟萃分析确定了博氏梭菌在减少复发方面的显著疗效(RR 0.59, 95% CI 0.35-0.98),而另一项荟萃分析得出结论,没有足够的证据推荐益生菌治疗艰难梭菌感染。结论:复发性艰难梭菌感染,单药治疗难治性患者可考虑鲍氏梭菌。
Literature Review of Saccharomyces boulardii in the Treatment of Refractory Recurrent Clostridium difficile Infection
Objective: To evaluate the efficacy of S. boulardii for the treatment of recurrent C. difficile infections. Methods: Eligible articles included S. boulardii in patients with recurrent C. difficile infection. The primary endpoint examined was clinical resolution of infection with no further recurrences during follow-up. Results: Six studies met inclusion criteria. A case report showed resolution of recurrences in one patient, and an experimental trial showed a trend towards decreased recurrences in patients receiving S. boulardii (85% no further recurrences). Two randomized controlled trials found a significant decrease in recurrences for S. boulardii versus placebo (34.6% vs 64.7%, P=0.04; 16.7% vs 50%, P=0.05). One meta-analysis determined significant efficacy for S. boulardii in reducing relapses (RR 0.59, 95% CI 0.35-0.98), while another concluded there was insufficient evidence to recommend probiotics for C. difficile infection. Conclusions: S. boulardii may be considered for patients with recurrent C. difficile infection, refractory to antibiotic regimens alone.